Eli Lilly’s stock soars as Mounjaro, Zepbound sales lead to a big profit beat

Date:

August 8, 2024

Eli Lilly’s stock was headed for its best day in a year on Thursday, after the drugmaker reported second-quarter earnings that rose well above forecasts, amid strength in sales of its diabetes and obesity treatments, Mounjaro and Zepbound.

Source link

Chime and Dave execs are coming to TechCrunch Disrupt 2024

Newsom's Mess: Fed Audit Finds Failure to Safeguard Millions of Dollars in Homelessness Funding

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Eli Lilly’s stock soars as Mounjaro, Zepbound sales lead to a big profit beat

Recent posts

Republicans clinch control of House, setting stage for quicker action on extending tax cuts

Spirit Airlines lowers revenue estimates as it faces more competition, capacity challenges

These maps show the oil and gas infrastructure in Francine’s path

Conagra’s stock drops after sales miss as frozen, refrigerated food prices fall

General Mills to sell North American yogurt business to French dairy companies for $2.1 billion

Mattel’s stock rallies on news of acquisition offer as Hasbro may enter the fray

What an August election-year rally for stocks could mean for Wall Street’s ‘Great Rotation’

Israeli strikes on Iran’s ‘oil island’ could send crude prices soaring

Obesity drugs’ next wave: These companies could snag 20% of GLP-1 market, analysts say

Temu and Shein face U.S. crackdown as Biden administration cites abuse of trade loophole

Super Micro needs a new CEO before its AI advantage erodes

Greenlight Capital’s clash with ex-staffer has hurt its business, lawsuit says

Money is the ‘tip of the iceberg’ in assessing big donors’ political influence, study finds

What will OPEC+ decide on oil output? Here’s why it’s complicated.

B. Riley Financial’s stock drops 30% after it suspends dividend and projects a loss

Related articles

RFK Jr. may start a food and drug ‘culture war.’ Investors are running for cover.

Here’s what bond and gold traders are signaling about Russia’s nuclear shift

Stock market ‘finally paying more attention to tariffs’ as a potential headwind

Investors are bracing for higher-for-even-longer interest rates

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

Manufacturing activity surges in New York region to highest level in nearly three years

RFK Jr. would rattle health markets as head of HHS, but his confirmation is far from certain, analyst says

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Company

Follow us